Long COVID Labs

Overview

Long COVID Labs (LCL) is a patient-led decentralized-science organization building an on-chain platform to find and deliver treatments for Long COVID – which it calls "the fastest growing chronic health condition in human history." It was incubated through the Bio Protocol launchpad as part of BIO Incubator Cohort 2, alongside Curetopia and Quantum Biology DAO.

LCL was founded by Rohan Dixit, a former neuroscientist at Stanford and the Harvard-MIT-MGH Martinos Center who contracted Long COVID after a mild 2020 infection and spent 2.5 years self-experimenting with therapies before co-founding the DAO. That origin shapes its defining feature: patients are treated as first-class stakeholders, not subjects – an inversion of a system where, in LCL's framing, "patients are excluded from decisions about their own care."

Where earlier BioDAOs such as VitaDAO organize around funding research and tokenizing its IP-NFTs, Long COVID Labs is structured as a therapeutics platform – its aim is to run trials and get treatments to patients directly, not only to fund upstream science.

The Long COVID problem

Long COVID affects roughly 100 million people globally and imposes an estimated $1 trillion per year in economic burden, per LCL's vision paper. The paper cites evidence that a single COVID infection is associated with an approximate 3–9 point IQ loss and may accelerate early-onset dementia – framing the condition as both a mass-scale and fast-growing chronic illness that traditional grant-and-trial pipelines are too slow to address.

LCL's thesis is that this mismatch – enormous, urgent patient demand versus a five-to-ten-year academic and regulatory timeline – is exactly the coordination failure a DAO can attack, by pooling patient data, community capital, and researcher effort in one incentive system.

The $COVID token and governance

Long COVID Labs is a decentralized autonomous organization wrapped in a Swiss non-profit and coordinated by the $COVID governance token. Of a 1 billion fixed supply – confirmed on Ethereum mainnet by the token contract's own totalSupply(), which returns exactly 1e9 – the vision paper allocates:

The token grants voting rights only – holders "do not receive any form of dividend or other revenue rights." Patients themselves hold a dedicated 10% of supply, giving the people who contribute clinical data a durable governance voice over research priorities.

The process is set out in the DAO's own first proposal, LCL DP-1, and it is two phases rather than the three a reader might expect. Phase 1 is four days of informal governance in the public Telegram channel (t.me/longcovidlabs, in the #Governance topic, the whole proposal in a single post); it advances only if it collects at least ten 👍 reactions including at least one from a named core-team member. Phase 2 is a three-day binding token vote on Snapshot, one token one vote. DP-1 describes the model as "tokenocratic voting." The longcovidlabs.eth space was created 30 January 2025 and counts weight through two Snapshot erc20-balance-of strategies – the liquid $COVID token and a separate vested vCOVID contract – so unvested contributor allocations vote alongside circulating supply.

The executed governance record

Six proposals have gone to a binding vote, all of them in 2025. Read in order they are a single story: a DAO asking its holders three times whether its own token should be tradable.

DP-2 asked holders to lift the transfer restriction, allocate 3% of supply plus matching treasury ETH to liquidity, and open an ETH/COVID pool. It drew the largest turnout in the DAO's history – 45 voters – and lost by better than three to one. Four months later DP-3 put the question again as a binary, with the core team arguing openly for the "no" side: it recommended delay on the grounds that "the core fundamentals (clinical traction and token utility) are not yet in place," and offered holders who wanted out a voluntary peer-to-peer OTC match at the original auction price – explicitly "not a buyback, refund, or liquidity program." Delay won with 90.8% of weight cast.

DP-4 and DP-5 opened the same day in August 2025 and show the concentration underneath those turnout figures. DP-4 set a standardized contributor allocation band of 0.01%–5% of supply on a 4-year vest with a 1-year cliff; DP-5 approved a $1,125,000 twelve-month budget itemised across five lines – $375,000 for an open-source treatment registry, $250,000 for research and evidence acceleration, $250,000 for biomarker development, $150,000 for marketing and growth, and $100,000 for a patient grant fund. Both passed with roughly 71 million tokens of weight cast by eleven and nine addresses respectively. The pattern – a ratified budget standing in for continuous votes – is the one described at bootstrap budgets and ratification votes.

DP-6 then authorized the Token Generation Event: launch on Ethereum mainnet on 20 November 2025 in connection with Devconnect, a $COVID/ETH Uniswap v3 pool "at a 0.3% fee tier" funded with $150,000 of treasury ETH plus matching tokens, and – the clause that ended the sequence – authority for the treasury multisig "to pursue additional listings on other DEXs and CEXs without requiring new governance proposals."

What the chain says happened next

The TGE executed, one day later than the date in the proposal. The live venue is a Uniswap v3 pool at 0x4Ba530…041d3f, created at block 23,848,831 on 21 November 2025 by an execTransaction on the treasury Safe at 0xab7ca711…c736316 – which is also one of the five addresses listed as administrators of the DAO's Snapshot space. The token's transfersEnabled() getter now returns true, and Blockscout counts 285 holders on 19 September 2026, down from 293 on 12 August.

Two details do not match the text holders approved. The pool that exists sits at the 1% fee tier, not the 0.3% tier DP-6 named – Uniswap's v3 factory returns the zero address for the 0.01%, 0.05% and 0.3% COVID/WETH pools, and there is no Uniswap v2 pair. That is a change of venue parameters rather than a breach: it is precisely the discretion DP-6's final clause granted the multisig. But it is only visible on-chain, because no proposal has been put to a vote since 7 October 2025 – the DAO's governance record stops at the proposal that authorized it to stop needing one.

The operating programme, meanwhile, is visibly running. LCL's own news index leads with an FDA-compliant patient registry now open, a $100,000 patient grant fund taking applications, a $22,000 grant to Dr. Michael Peluso to study SARS-CoV-2 spike protein persistence in blood, and an AI tool analysing the Long COVID patient conversation. Three of those four map directly onto DP-5's budget lines. What LCL demonstrates is not a dormant DAO but a decoupled one: the treasury executes the mandate it was given, and the vote is what granted the mandate rather than what steers it.

The Moonshot app and the treatment leaderboard

Since early 2026 the platform has had a consumer front door. Long COVID Labs Moonshot is a mobile app on iOS and Android that lets patients track symptoms, connect wearables, and contribute to the IRB-approved patient registry. Its App Store listing gives the harder numbers than any announcement does: first released 27 January 2026, and still shipping – version 1.3 was published on 1 September 2026, read here on 19 September 2026. The listed publisher is "Long COVID Moonshot Company", a corporate entity distinct from the Swiss Verein that wraps the DAO.

The website carries the second half of the product: a public treatment leaderboard ranking eleven candidate therapies – Pemgarda and Paxlovid at the top, down through metformin, PEG interferon lambda and molnupiravir – each tagged with a research stage from "Discovery" to "Trial design" and a community rating, with a "Learn More & Vote" control beside every row. That is a second, softer voting surface running alongside the dormant Snapshot space: patients rank research priorities continuously in the app while the token's binding governance has been quiet since October 2025. Whether the leaderboard's ratings bind anything is not stated, which is the distinction a reader should hold onto.

The organisation is otherwise visibly working. Its newest first-party post, dated 21 August 2026, reports a letter submitted to the FDA advocating greater patient access to re-purposed drugs – an advocacy line the DP-5 budget did not itemise, and a reminder that the decoupling described above runs in both directions: the treasury acts on a mandate the electorate has not revisited in over a year.

The Adaptive Trial Engine

LCL's core technical bet is an Adaptive Trial Engine: instead of a handful of large, sequential trials, the platform is designed to run thousands of small adaptive clinical trials in parallel, using Bayesian inference to continuously update each treatment's success probability as patient data streams in, and machine learning to reallocate participants toward the arms that are working.

The vision paper's roadmap phases this in: DAO establishment plus initial drug-repurposing studies (Q1 2025), the parallel adaptive-trial platform for antivirals and immune modulators (Q4 2025), scaling to dozens of trials and thousands of participants (Q3 2026), and permanent decentralized-research infrastructure beyond. LCL's first treatment candidate combines a long-acting monoclonal antibody with a viral-replication inhibitor, and its near-term strategy repurposes existing therapies such as Pemgarda and Paxlovid while contributors from Stanford, Mt. Sinai, and UCSF develop novel treatments. The registry and the patient grant fund are the parts of that roadmap with dated, first-party evidence behind them; the parallel-trial platform itself has no comparable public milestone.

Data, patients and IP

The model turns patient data contribution into governance stake: patients supply structured trial and real-world data, earn $COVID, and shape which treatments get prioritized – a concrete example of the research-data-ownership thesis that the people who generate biomedical data should share in its value.

On commercialization, LCL describes three IP pathways: licensing university-lab discoveries, licensing existing pharmaceutical IP for Long COVID re-purposing, and sponsoring internal research the DAO owns outright. In each case the stated intent is a "virtuous cycle" – profits from any resulting therapy flow back into the treasury and are reinvested into further research, rather than accruing solely to outside shareholders.

Place in the Bio Protocol ecosystem

Long COVID Labs sits in the Bio Protocol (bio.xyz) portfolio alongside VitaDAO (longevity), AthenaDAO (women's health), Cerebrum DAO (brain health), CryoDAO (cryopreservation) and Curetopia (rare disease). During its January 2025 auction, LCL distributed 1% of supply to $BIO holders who participated with ETH – the launchpad's standard curation-and-alignment mechanism.

Its distinguishing move within that set is the therapeutics-platform posture: most BioDAOs fund and tokenize research; LCL is trying to own the trial-to-treatment loop for a single, very large indication.

How Caper approaches this

Long COVID Labs spent eight months and three votes on a question Caper never puts to a vote. A caper's governance token is minted once at creation with no mint or burn roles at all and no transfer restriction, and it trades on its bonding curve from the first block – there is no transfer switch to flip, no liquidity proposal to lose, and no treasury ETH to pair against it. Raising funds and enabling trading are the same act.

What is restricted is the thing LCL's design leaves liquid. A caper mints a separate soulbound proof-of-vote token on exactly one act – one per ranked ballot cast (VOTE_MINT = 1), with buying and selling minting none: only the caper's own component can deposit it, so it cannot be transferred between accounts, and a holder can withdraw it for exactly one purpose – to feed it back in on exit. A member's canonical vote weight is w = (t · v) / (V · T), so holdings and accumulated votes are multiplicative factors: a large holder who has never cast a ballot carries zero weight, and so does a frequent voter holding nothing. Buying more still raises your weight – the point is that it is not sufficient on its own, and that no amount of it mints the other factor.

The other half of the LCL story is the harder one, and Caper answers it structurally rather than culturally. DP-6's mandate to act "without requiring new governance proposals" is what a DAO grants when the cost of a vote is high enough that governing continuously is impractical. In a caper the treasury has no discretionary path at all: every movement of value is a typed proposal that passed – PAYOUT, INVEST, DIVEST, METADATA, or (for $CAPER, executive-only) UPGRADE – so there is no standing authorization for a multisig to exercise, because there is no multisig.